ACTU NASDAQ
Actuate Therapeutics Inc
1W: -17.0%
1M: -8.4%
3M: -43.5%
YTD: -60.2%
1Y: -77.2%
$2.40
-0.03 (-1.23%)
Pre-Market: $2.45 (+0.05, +1.88%)
Weekly Expected Move ±20.7%
$2
$2
$3
$3
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$57.4M
52W Range1.58-11.99
Volume52,980
Avg Volume139,652
Beta0.93
Dividend—
Analyst Ratings
Company Info
CEODaniel Schmitt
Employees10
SectorHealthcare
IndustryBiotechnology
IPO Date2024-08-13
Websiteactuatetherapeutics.com
1751 River Run
Fort Worth, TX 76107
US
Fort Worth, TX 76107
US
817 887 8455
About Actuate Therapeutics Inc
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Latest News
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Huber Martin H. Jr. | 30,000 | $3.00 | 2026-05-01 | |
| SCHMITT DANIEL M | A-Award | 237,000 | $2.49 | 2026-04-01 |
| Mazar Andrew Paul | A-Award | 105,000 | $2.49 | 2026-04-01 |
| LYTLE PAUL J | A-Award | 105,000 | $2.49 | 2026-04-01 |
| SCHMITT DANIEL M | M-Exempt | 272,055 | — | 2026-02-13 |